Biotech and Pharma Stocks

Small Caps is Australia's #1 site for market news & information on ASX listed small cap companies.

Small Caps and affiliated companies accept no responsibility for any claim, loss or damage as a result of information provided or its accuracy. The information provided on this site is general in nature, not financial product advice, see a financial expert before making any investment decision. Your personal objectives, financial situation or needs have not been taken into consideration. There may be a conflict of interest present with commercial arrangements with companies and/or stock held. Small Caps or an associate may receive a commission for funds raised.

BIOTECH & PHARMA

Botanix Pharmaceuticals tracks commercial dermatology path

PharmAust receives tablets for motor neurone disease clinical trial

Incannex Healthcare closes in on completing APIRx Pharmaceuticals acquisition

PharmAust expands phase 2 canine B cell lymphoma MPL trial to US

Pre-clinical study shows Incannex Healthcare’s IHL-216A rapidly restores spatial memory after sports-related concussion

Argenica steps closer to clinical studies of stroke drug ARG-007 following positive preclinical safety results

Botanix acquires novel medical dermatology asset to treat axillary hyperhidrosis

Incannex’s psychedelic developments lead progress in March quarter

PharmAust latest report gives green light for continuing trials

Argenica Therapeutics toxicology studies indicate key findings ahead of ARG-007 clinical trial

Kazia Therapeutics establishes ‘at-the-market’ equity program

Kazia Therapeutics completes phase II trial of paxalisib in glioblastoma

PharmAust receives $708,000 in R&D tax refund, strengthens financial position for upcoming clinical trials

Invex Therapeutics continues preparation ahead of IIH EVOLVE phase three clinical trial

Kazia Therapeutics’ paxalisib shows activity against rare childhood brain cancer in pre-clinical research

PharmAust moves closer to clinical trial of MPL in motor neuron disease

Prescient Therapeutics begins recruiting for expanded trial of PTX-100 in blood cancer

InhaleRx achieves critical milestone with licence to store and sell controlled substances

Argenica Therapeutics records positive results from ARG-007 study into cerebral ischaemia

Incannex Healthcare to acquire APIRx Pharmaceuticals for 22 projects and big patent portfolio

Argenica Therapeutics publishes scientific paper on ARG-007 ahead of clinical trials